Holen Sie sich die Stockscreener-App
8.49
2.08%
-0.18
Vorhandelsmarkt:
8.59
0.10
+1.18%
Schlusskurs vom Vortag:
$8.67
Offen:
$8.61
24-Stunden-Volumen:
1.20M
Relative Volume:
1.22
Marktkapitalisierung:
$634.05M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-27.03M
KGV:
-15.16
EPS:
-0.56
Netto-Cashflow:
$-23.97M
1W Leistung:
+0.59%
1M Leistung:
+7.33%
6M Leistung:
+99.76%
1J Leistung:
+5.86%
1-Tages-Spanne:
$8.31
$8.74
1-Wochen-Bereich:
$8.31
$9.60
52-Wochen-Spanne:
$2.54
$9.60
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
Firmenname
Corvus Pharmaceuticals Inc
Sektor
Branche
Telefon
(650) 900-4520
Adresse
863 MITTEN ROAD, BURLINGAME, CA
Vergleichen Sie CRVS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRVS
Corvus Pharmaceuticals Inc
|
8.49 | 647.49M | 0 | -27.03M | -23.97M | -0.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-13 | Eingeleitet | Barclays | Overweight |
| 2025-01-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-08-18 | Eingeleitet | Oppenheimer | Outperform |
| 2021-12-01 | Fortgesetzt | Jefferies | Buy |
| 2021-05-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-02-10 | Herabstufung | Mizuho | Buy → Neutral |
| 2019-09-12 | Eingeleitet | Mizuho | Buy |
| 2019-05-29 | Eingeleitet | ROTH Capital | Buy |
| 2017-08-24 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2017-05-01 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2016-04-18 | Eingeleitet | Credit Suisse | Outperform |
| 2016-04-18 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Corvus Pharmaceuticals Inc Aktie (CRVS) Neueste Nachrichten
What is Corvus Pharmaceuticals Inc (CRVS) Stock Return on Shareholders’ Capital? - Setenews
Corvus Pharmaceuticals (NASDAQ:CRVS) Trading 7.1% HigherWhat's Next? - MarketBeat
Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - The Manila Times
Corvus Pharmaceuticals Reports Promising Phase 1 Data for Soquelitinib in Relapsed/Refractory T Cell Lymphoma at ASH Annual Meeting - Quiver Quantitative
Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial - Yahoo Finance
Corvus Pharma (CRVS) Stock Analysis Report | Financials & Insights - Benzinga
Corvus Pharmaceuticals (NASDAQ:CRVS) Sets New 12-Month HighHere's What Happened - MarketBeat
You might want to take a look at Corvus Pharmaceuticals Inc (CRVS) now - Setenews
Will Corvus Pharmaceuticals Inc. stock split again soonMarket Performance Report & Growth Focused Investment Plans - Newser
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Price Down 8%Here's What Happened - MarketBeat
Here's Why We're Not Too Worried About Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation - Yahoo Finance
Is Corvus Pharmaceuticals Inc. stock a buy before product launchesDividend Hike & Intraday High Probability Alerts - Newser
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Perhaps timely catching Corvus Pharmaceuticals Inc (CRVS) would be a good idea - Setenews
Foresite Capital Management VI LLC Boosts Position in Corvus Pharmaceuticals, Inc. $CRVS - MarketBeat
Corvus Pharmaceuticals: Trial Momentum Keeps Stock In Focus - RTTNews
What risks investors should watch in Corvus Pharmaceuticals Inc. stockWeekly Trend Summary & Weekly Watchlist for Consistent Profits - newser.com
Will Corvus Pharmaceuticals Inc. stock reach Wall Street targetsPortfolio Growth Summary & Technical Buy Zone Confirmation - newser.com
Is Corvus Pharmaceuticals Inc. stock affected by interest rate hikes2025 Geopolitical Influence & Consistent Profit Trading Strategies - newser.com
Is Corvus Pharmaceuticals Inc. stock supported by innovation pipeline2025 Analyst Calls & Consistent Profit Trading Strategies - newser.com
What valuation multiples suggest for Corvus Pharmaceuticals Inc. stockRecession Risk & AI Forecast Swing Trade Picks - newser.com
Corvus Pharmaceuticals Inc. stock momentum explainedWeekly Profit Report & Verified Swing Trading Watchlist - newser.com
Its Stock Has Paid Off Big Time For Corvus Pharmaceuticals Inc - Setenews
BML Capital Management LLC Buys New Stake in Corvus Pharmaceuticals, Inc. $CRVS - MarketBeat
Corvus Pharmaceuticals Inc. recovery potential after sell offPortfolio Update Summary & Safe Capital Growth Tips - newser.com
Using RSI to spot recovery in Corvus Pharmaceuticals Inc.Earnings Growth Report & Long-Term Growth Portfolio Plans - newser.com
Combining price and volume data for Corvus Pharmaceuticals Inc.July 2025 Decliners & Reliable Momentum Entry Alerts - newser.com
Is Corvus Pharmaceuticals Inc. forming a bottoming baseTrade Risk Summary & Fast Moving Stock Watchlists - newser.com
What drives Corvus Pharmaceuticals Inc stock priceEarnings Miss Alerts & Free Wealth Planning Blueprints - earlytimes.in
Published on: 2025-11-28 13:27:18 - earlytimes.in
Is Corvus Pharmaceuticals Inc a good long term investmentEconomic Impact on Stocks & Double Digit Capital Growth - earlytimes.in
What machine learning models say about Corvus Pharmaceuticals Inc.Weekly Profit Analysis & Reliable Breakout Stock Forecasts - newser.com
How to build a dashboard for Corvus Pharmaceuticals Inc. stockJuly 2025 Selloffs & Fast Momentum Stock Entry Tips - newser.com
Is Corvus Pharmaceuticals Inc. stock a defensive play in 2025July 2025 Recap & Long-Term Safe Investment Ideas - newser.com
Should you wait for a breakout in Corvus Pharmaceuticals Inc.Index Update & Safe Entry Zone Tips - newser.com
Get in on Corvus Pharmaceuticals Inc’s (CRVS) buy-in window today! - Setenews
Finanzdaten der Corvus Pharmaceuticals Inc-Aktie (CRVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):